AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Press Release: Amarillo Biosciences Inc licenses rights to low dose oral interferon for hepatitis B in 40 African countries; and executes dietary supplement agreement for Korea.
(From Chemical Business NewsBase: Press Release)
Amarillo Biosciences Inc (Amarillo) announces the company has signed a licensing agreement with African Health Solutions LLC, Greenville, DE, providing the rights to oral low-dose interferon alpha for the treatment of hepatitis B patients in Africa. The President and CEO of Amarillo said that data from the human clinical trials and the mechanism of action studies show that the low-dose oral interferon alpha is biologically active and well …
